While Big Pharma pushes misguided policies targeting pharmacy benefits as part of a blame game designed to keep prescription drug prices high, former Members of Congress are reminding current lawmakers that they’ve seen this movie before. Congress has considered similar
With the recent launch of a new adalimumab biosimilar, the U.S. biosimilar market is becoming more competitive, increasing the potential for these more affordable options to play a critical role in helping to lower prescription drug costs for Americans. As biosimilar competition
(Washington, D.C.) — Today, members of the prescription drug supply and payment chain, including pharmacy benefit managers (PBMs), pharmaceutical manufacturers, pharmacies, including specialty and managed care pharmacies, and health plans, sent a letter to Vice President Mike Pence and congressional
In case you missed it, a new article in The Atlantic explains how big drug companies commonly use an anti-competitive tactic, “pay-for-delay,” to prevent more affordable options from entering the marketplace.
The Honorable Michael R. Pence Vice President of the United States Chair of the White House Coronavirus Task Force The White House 1600 Pennsylvania Avenue, N.W. Washington, DC 20500 Dear Mr. Vice President: As our nation works tirelessly to address
In case you missed it, Katie Payne, senior vice president for strategic communications for the Pharmaceutical Care Management Association (PCMA), discusses how the BIO International Convention happening this week in Boston, MA misses the critical opportunity to address the root
Speakers Discuss Pharmacy Benefit Company Innovations, Importance of Protecting Cost Saving Role, and Solutions to Improve Affordability
With the United States in a debate on high drug prices, solutions are being sought that will lower the cost to consumers and taxpayers, while increasing access. However, care must be taken at the federal level to not make changes
New Research Paper Demonstrates Declining Biosimilars Prices and Increasing Health Plan Coverage (Washington, D.C.) — Pharmacy benefit managers, PBMs, support the proliferation and use of biosimilars. A robust biosimilar market will increase competition for biologic drugs and provide added choice
Prescription drug list prices in the United States continue to be a source of frustration for patients and policymakers alike. The administration is pushing forward with new ideas for lower list prices and lower costs for consumers. As the only
©2024 PCMA. All Rights Reserved.
